Express Pharma
Home  »  Latest Updates  »  Aurobindo Pharma receives approval for Azithromycin for injection and Entacapone tabs

Aurobindo Pharma receives approval for Azithromycin for injection and Entacapone tabs

45
Read Article

Azithromycin for injection is indicated for treatment of patients with community-acquired pneumonia and pelvic inflammatory disease

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (US FDA) to manufacture and market Azithromycin for Injection USP, 500mg /vial (ANDA 203294). The company has also received approval to manufacture and market Entacapone tablets USP, 200mg (ANDA 203437). The product will be launched soon.

Azithromycin for injection USP, 500mg /vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax (Azithromycin for injection) 500mg/vial of Pfizer. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as community-acquired pneumonia and pelvic inflammatory disease.

Entacapone tablets are used in the treatment of Parkinson’s disease and has an estimated market size of $59 million for the twelve months ending April 2015 according to IMS.

Comments are closed.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Know Importance of using different levels of Controls
Register Now!
close-image